Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belrestotug (Primary) ; Dostarlimab (Primary) ; GSK 4381562 (Primary) ; HS-20093 (Primary) ; Nelistotug (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline; GSK; Surface Oncology

Most Recent Events

  • 12 Nov 2024 Number of treatment arms are increased from 4 to 9 by the addition of 5 more new experimental arms E,F, G, H and I, with different newly added drugs (Belrestotug, Nelistotug and HS-20093 (GSK5764227)) and drug combinations.
  • 12 Nov 2024 Planned primary completion date changed from 14 Oct 2026 to 12 Sep 2028.
  • 12 Nov 2024 Planned End Date changed from 14 Oct 2026 to 12 Sep 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top